Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

Giuseppe Lapadula; Silvia Costarelli; Liliane Chatenoud; Francesco Castelli; Noemi Astuti; Simona Di Giambenedetto; Eugenia Quiros-Roldan; Laura Sighinolfi; Nicoletta Ladisa; Massimo Di Pietro; Alessia Zoncada; Elisa Di Filippo; Andrea Gori; Paola Nasta; Carlo Torti

doi:10.1097/QAI.0000000000000585

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

Giuseppe Lapadula
, Silvia Costarelli
, Liliane Chatenoud
, Francesco Castelli
, Noemi Astuti
, Simona Di Giambenedetto
, Eugenia Quiros-Roldan
, Laura Sighinolfi
, Nicoletta Ladisa
, Massimo Di Pietro
, Alessia Zoncada
, Elisa Di Filippo
, Andrea Gori
, Paola Nasta
, Carlo Torti

AO San Gerardo De' Tintori
IRCCS Istituto di ricerche farmacologiche Mario Negri - Milano, Bergamo, Ranica
University of Brescia
Ospedali Riuniti di Bergamo
Ospedale Sant'Anna
Osp. Consorziale Policlin.
Azienda Sanitaria di Firenze
Azienda Ospedaliera di Cremona
Spedali Civili Di Brescia

Risultato della ricerca: Contributo in rivista › Articolo

11 Citazioni (Scopus)

Abstract

The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.

Lingua originale	Inglese
pagine (da-a)	312-318
Numero di pagine	7
Rivista	Journal of Acquired Immune Deficiency Syndromes (1999)
Volume	69
DOI	https://doi.org/10.1097/QAI.0000000000000585
Stato di pubblicazione	Pubblicato - 2015

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Adult
Anti-HIV Agents
Cohort Studies
Drug Therapy, Combination
Female
HIV Infections
Hepatitis B
Hepatitis C
Humans
Italy
Liver
Male
Middle Aged
Protease Inhibitors
Risk Factors
Ritonavir

Accesso al documento

10.1097/QAI.0000000000000585

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Lapadula, G., Costarelli, S., Chatenoud, L., Castelli, F., Astuti, N., Di Giambenedetto, S., Quiros-Roldan, E., Sighinolfi, L., Ladisa, N., Di Pietro, M., Zoncada, A., Di Filippo, E., Gori, A., Nasta, P., & Torti, C. (2015). Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 69, 312-318. https://doi.org/10.1097/QAI.0000000000000585

@article{14399ab361b44b7da178bc00c0ca1d5e,

title = "Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients",

abstract = "The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.",

keywords = "Adult, Anti-HIV Agents, Cohort Studies, Drug Therapy, Combination, Female, HIV Infections, Hepatitis B, Hepatitis C, Humans, Italy, Liver, Male, Middle Aged, Protease Inhibitors, Risk Factors, Ritonavir, Adult, Anti-HIV Agents, Cohort Studies, Drug Therapy, Combination, Female, HIV Infections, Hepatitis B, Hepatitis C, Humans, Italy, Liver, Male, Middle Aged, Protease Inhibitors, Risk Factors, Ritonavir",

author = "Giuseppe Lapadula and Silvia Costarelli and Liliane Chatenoud and Francesco Castelli and Noemi Astuti and \{Di Giambenedetto\}, Simona and Eugenia Quiros-Roldan and Laura Sighinolfi and Nicoletta Ladisa and \{Di Pietro\}, Massimo and Alessia Zoncada and \{Di Filippo\}, Elisa and Andrea Gori and Paola Nasta and Carlo Torti",

year = "2015",

doi = "10.1097/QAI.0000000000000585",

language = "English",

volume = "69",

pages = "312--318",

journal = "Journal of Acquired Immune Deficiency Syndromes (1999)",

issn = "1525-4135",

publisher = "Wolters Kluwer Health",

}

Lapadula, G, Costarelli, S, Chatenoud, L, Castelli, F, Astuti, N, Di Giambenedetto, S, Quiros-Roldan, E, Sighinolfi, L, Ladisa, N, Di Pietro, M, Zoncada, A, Di Filippo, E, Gori, A, Nasta, P & Torti, C 2015, 'Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients', Journal of Acquired Immune Deficiency Syndromes (1999), vol. 69, pagg. 312-318. https://doi.org/10.1097/QAI.0000000000000585

TY - JOUR

T1 - Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

AU - Lapadula, Giuseppe

AU - Costarelli, Silvia

AU - Chatenoud, Liliane

AU - Castelli, Francesco

AU - Astuti, Noemi

AU - Di Giambenedetto, Simona

AU - Quiros-Roldan, Eugenia

AU - Sighinolfi, Laura

AU - Ladisa, Nicoletta

AU - Di Pietro, Massimo

AU - Zoncada, Alessia

AU - Di Filippo, Elisa

AU - Gori, Andrea

AU - Nasta, Paola

AU - Torti, Carlo

PY - 2015

Y1 - 2015

N2 - The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.

AB - The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.

KW - Adult

KW - Anti-HIV Agents

KW - Cohort Studies

KW - Drug Therapy, Combination

KW - Female

KW - HIV Infections

KW - Hepatitis B

KW - Hepatitis C

KW - Humans

KW - Italy

KW - Liver

KW - Male

KW - Middle Aged

KW - Protease Inhibitors

KW - Risk Factors

KW - Ritonavir

KW - Adult

KW - Anti-HIV Agents

KW - Cohort Studies

KW - Drug Therapy, Combination

KW - Female

KW - HIV Infections

KW - Hepatitis B

KW - Hepatitis C

KW - Humans

KW - Italy

KW - Liver

KW - Male

KW - Middle Aged

KW - Protease Inhibitors

KW - Risk Factors

KW - Ritonavir

UR - http://hdl.handle.net/10807/68425

U2 - 10.1097/QAI.0000000000000585

DO - 10.1097/QAI.0000000000000585

M3 - Article

SN - 1525-4135

VL - 69

SP - 312

EP - 318

JO - Journal of Acquired Immune Deficiency Syndromes (1999)

JF - Journal of Acquired Immune Deficiency Syndromes (1999)

ER -

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo